Relevant bibliographies by topics / Pharmaceutical Manufacturers Association of Canada

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Pharmaceutical Manufacturers Association of Canada'

Author: Grafiati

Published: 4 June 2021

Last updated: 28 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical Manufacturers Association of Canada.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical Manufacturers Association of Canada"

Lexchin, Joel. "Canadian Marketing Codes: How Well are They Controlling Pharmaceutical Promotion?" International Journal of Health Services 24, no. 1 (1994): 91–104. http://dx.doi.org/10.2190/ekep-d9je-31a4-kte5.

Full text

Abstract:

Pharmaceutical promotion in Canada is controlled by two codes: a voluntary one developed by the Pharmaceutical Advertising Advisory Board dealing mostly with printed promotional material, and one from the Pharmaceutical Manufacturers Association of Canada covering other forms of promotion. This article looks at enforcement of the provisions of these codes and at areas in which they are deficient. One of the major weaknesses in both codes is their lack of effective sanctions for companies that violate their provisions. Strong codes are necessary because many physicians rely heavily on promotion

APA, Harvard, Vancouver, ISO, and other styles

Dolovich, Myrna B., and Jolyon P. Mitchell. "Canadian Standards Association Standard CAN/CSA/Z264.1-02:2002: A New Voluntary Standard for Spacers and Holding Chambers Used with Pressurized Metered-Dose Inhalers." Canadian Respiratory Journal 11, no. 7 (2004): 489–95. http://dx.doi.org/10.1155/2004/497946.

Full text

Abstract:

A new Canadian standard (CAN/CSA/Z264.1-02:2002) has been published with the purpose of helping to ensure the safety, efficacy and functionality of spacers and/or holding chambers. They are prescribed for use by spontaneously breathing patients for the treatment of various respiratory diseases where medication is delivered to the lungs using pressurized-metered dose inhalers. This consensus standard was developed with the support of pharmaceutical companies and manufacturers of spacers and holding chambers, and with the help of clinicians, retail pharmacists and representatives of patient advo

APA, Harvard, Vancouver, ISO, and other styles

Parke, Dennis V., Costas Ioannides, and David F. V. Lewis. "The 1990 Pharmaceutical Manufacturers Association of Canada Keynote Lecture. The role of the cytochromes P450 in the detoxication and activation of drugs and other chemicals." Canadian Journal of Physiology and Pharmacology 69, no. 5 (1991): 537–49. http://dx.doi.org/10.1139/y91-081.

Full text

Abstract:

The roles of the cytochromes P450 are reviewed, with emphasis on their involvement in the detoxication of drugs and chemicals, the activation of carcinogens, and the toxicity of drugs. Cytochromes P450 have different characteristics. P450I mostly activates carcinogens and other chemicals by forming oxygenated reactive intermediates, which are also associated with the formation of neoantigens and immunotoxicity. P450IIE has a propensity to form oxygen radicals, which are cytotoxic and carcinogenic; other cytochromes generate oxygen radicals by futile cycling when activated by difficultly metabo

APA, Harvard, Vancouver, ISO, and other styles

Clarke, Philippa, and Angela Colantonio. "Wheelchair Use Among Community-Dwelling Older Adults: Prevalence and Risk Factors in a National Sample." Canadian Journal on Aging / La Revue canadienne du vieillissement 24, no. 2 (2005): 191–98. http://dx.doi.org/10.1353/cja.2005.0059.

Full text

Abstract:

ABSTRACTOlder adults are the largest group of wheelchair users yet there are no peer-reviewed studies on the national profile of older wheelchair users in Canada. We investigated the characteristics of wheelchair users in a national sample of community-dwelling older adults from the Canadian Study of Health and Aging (CSHA-2). Questions on the use of assistive technology were asked of 5395 Canadians (over 64), and 4.6 per cent reported using a wheelchair. Logistic regression was used to model the factors associated with wheelchair use. Controlling for age, gender, and cognitive impairment, old

APA, Harvard, Vancouver, ISO, and other styles

Gerber, Patricia E., and Larry D. Lynd. "Selective Serotonin-Reuptake Inhibitor–Induced Movement Disorders." Annals of Pharmacotherapy 32, no. 6 (1998): 692–98. http://dx.doi.org/10.1345/aph.17302.

Full text

Abstract:

OBJECTIVE: To compile and evaluate all available data suggesting an association between selective serotonin-reuptake inhibitor (SSRI) administration and the occurrence of movement disorders, and to characterize these reactions in terms of onset, duration, treatment and outcome, and potential predisposing factors. METHODOLOGY: Reports of movement disorders were identified by conducting a comprehensive literature search that included tertiary adverse drug reaction resources, MEDLINE, EmBASE, Biological Abstracts, Current Contents, Reactions, ClinAlert, and International Pharmaceutical Abstracts.

APA, Harvard, Vancouver, ISO, and other styles

Kashyntseva, Oksana. "Pharmaceutical nationalism as an instrument to ensure the access to medicines." Theory and Practice of Intellectual Property, no. 2 (July 6, 2021): 101–6. http://dx.doi.org/10.33731/22021.236692.

Full text

Abstract:

Keywords: pharmaceutical nationalism, access to drugs, compulsory licensing, governmentuse, exclusion from intellectual property rights The article concerns the emergence of the phenomena of«pharmaceutical nationalism» in the year of the COVID-19 pandemic. Pharmaceuticalnationalism is manifested in the qualitative and quantitative aspects. In the contextof a qualitative manifestation of pharmaceutical nationalism, we presume the politicalwill on establishing of a new state protectionist policy to local manufacturers ofmedicines, the establishing of preferences, exemptions of the patent m

APA, Harvard, Vancouver, ISO, and other styles

Gardner, David M., and Larry D. Lynd. "Sumatriptan Contraindications and the Serotonin Syndrome." Annals of Pharmacotherapy 32, no. 1 (1998): 33–38. http://dx.doi.org/10.1345/aph.17204.

Full text

Abstract:

OBJECTIVE To determine the risk for serotonin syndrome associated with the concomitant use of sumatriptan and the currently contraindicated therapies, that is, the monoamine oxidase inhibitors (MAOIs), serotonin selective-reuptake inhibitors (SSRIs), and lithium. METHODOLOGY: A comprehensive search for reports of serotonin syndrome associated with sumatriptan use was conducted by using tertiary drug interaction literature, MEDLINE, EmBASE, Biological Abstracts, Current Contents, Reactions, ClinAlert, and the International Pharmaceutical Abstracts. In addition, related reports from the propriet

APA, Harvard, Vancouver, ISO, and other styles

Thanh, Nguyen Xuan, Anderson W. Chuck, Arto Ohinmaa, and Philip Jacobs. "BENEFITS OF PHARMACEUTICAL INNOVATION: THE CASE OF SIMVASTATIN IN CANADA." International Journal of Technology Assessment in Health Care 28, no. 4 (2012): 390–97. http://dx.doi.org/10.1017/s0266462312000499.

Full text

Abstract:

Background: The benefits of pharmaceutical innovations are widely diffused; they accrue to the healthcare providers, patients, employers, and manufacturers. We estimate the societal monetary benefits of simvastatin in Canada and its distribution among different beneficiaries overtime.Methods: Monetary benefits to developing and generic manufacturers were estimated by calculating public and private revenues minus the development costs of simvastatin and the contribution toward further research and development. We used a dynamic Markov model to estimate monetary benefits to healthcare and employ

APA, Harvard, Vancouver, ISO, and other styles

Weaver, Lawrence C. "A View from the Pharmaceutical Manufacturers Association." American Journal of Pharmaceutical Education 49, no. 4 (1985): 381–82. http://dx.doi.org/10.1016/s0002-9459(24)09956-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Kobayashi, Satoshi. "DRUG INTERACTION WORKING GROUP : JAPAN PHARMACEUTICAL MANUFACTURERS ASSOCIATION." Drug Metabolism and Pharmacokinetics 14, supplement (1999): 150–51. http://dx.doi.org/10.2133/dmpk.14.supplement_150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Pharmaceutical Manufacturers Association of Canada"

MacLeod, Suzanne. "From the "rising tide" to solidarity: disrupting dominant crisis discourses in dementia social policy in neoliberal times." Thesis, 2014. http://hdl.handle.net/1828/5213.

Full text

Abstract:

As a social worker practising in long-term residential care for people living with dementia, I am alarmed by discourses in the media and health policy that construct persons living with dementia and their health care needs as a threatening “rising tide” or crisis. I am particularly concerned about the material effects such dominant discourses, and the values they uphold, might have on the collective provision of care and support for our elderly citizens in the present neoliberal economic and political context of health care. To better understand how dominant discourses about dementia work at t

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Pharmaceutical Manufacturers Association of Canada"

Pharmaceutical Manufacturers Association of Canada. Code of marketing practices. Pharmaceutical Manufacturers Association of Canada, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Pharmaceutical Manufacturers Association of Canada. General Meeting. Partners in change: Health care in Canada to the year 2000 : six presentations made at the 74th Annual General Meeting of the Pharmaceutical Manufacturers Association of Canada, April 1988. Pharmaceutical Manufacturers Association of Canada, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Meeting, Pharmaceutical Manufacturers Association of Canada General. On being 75: An ageing society : presentations made at the 75th annual General Meeting of the Pharmaceutical Manufacturers Association of Canada, November 3-4, 1989. The Association, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Raman-Wilms, Lalitha. Canadian Pharmacists Association guide to drugs in Canada. 3rd ed. Edited by Canadian Pharmacists Association. Dorling Kindersley, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

ltd, Buchan Lawton Parent, and Ontario Research Foundation, eds. Cellulose Insulation Manufacturers' Association of Canada developmental house monitoring: Prepared for the Ontario Research Foundation. Energy, Mines and Resources Canada, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Association, Canadian Pharmaceutical. The Canadian Pharmaceutical Association response to the National Forum on Health report on pharmaceuticals. The Association, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

National Institutes of Health (U.S.) and Pharmaceutical Manufacturers Association, eds. Report of the National Conference on Orphan Drugs: The path to promise : May 18-19, 1988, George Washington University, Washington, D.C. / [sponsored jointly by] the National Institutes of Health and the Pharmaceutical Manufacturers Association. The Institutes, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

A Decima research report to the Pharmaceutical Manufacturers Association of Canada. Decima Research, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Schweitzer, Stuart O., and Z. John Lu. The Global Pharmaceutical Industry. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780190623784.003.0005.

Full text

Abstract:

This chapter examines the supply of pharmaceuticals worldwide, including production and sales, R&D, traditional medicines, and international trade. Worldwide consolidation of drug manufacturers, a trend dating back to the early 1990s, will also be examined. The discussion focuses on the unique characteristics of the industry in several key regions and countries, including the Europe Union, China, Japan, India, and Brazil. This chapter also looks at the impact of government price control on pharmaceutical R&D in Canada and Australia. Issues regarding access to innovative medicines in de

APA, Harvard, Vancouver, ISO, and other styles

Roaf, James Richardson. A Letter to an English Friend From a Member of the Canadian Manufacturers Association Party of England, June 1905: Written After the Return to Canada (Classic Reprint). Forgotten Books, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Pharmaceutical Manufacturers Association of Canada"

Nahler, Gerhard. "Pharmaceutical Manufacturers Association (PMA)." In Dictionary of Pharmaceutical Medicine. Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-89836-9_1041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Nahler, Gerhard. "International Federation of Pharmaceutical Manufacturers Association (IFPMA)." In Dictionary of Pharmaceutical Medicine. Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-89836-9_720.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Savello, David R. "Highlights of the Pharmaceutical Research and Manufacturers Association proposal for FDA reform." In Improving the Regulatory Review Process. Springer Netherlands, 1996. http://dx.doi.org/10.1007/978-94-009-1788-0_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

"Marketing Pharmaceuticals." In Pharmaceutical Economics And Policy, edited by Stuart O. Schweitzer. Oxford University PressNew York, NY, 2006. http://dx.doi.org/10.1093/oso/9780195300956.003.0005.

Full text

Abstract:

Abstract The pharmaceutical industry produces a great number of new products each year, and it is crucial that prescribers be informed about the innovations on a continuing basis. This activity is marketing. According to a report by the Pharmaceutical Research and Manufacturers of America (PhRMA) (2002a, 2002b), formerly the Pharmaceutical Manufacturers Association, pharmaceutical companies employed nearly 225,000 people in 2000, with 39% of these employees being involved in marketing, with 22% in research and development (R&D), and 26% in production. The size of the marketing effort in te

APA, Harvard, Vancouver, ISO, and other styles

"Pricing Pharmaceuticals in a World Environment." In Pharmaceutical Economics And Policy, edited by Stuart O. Schweitzer. Oxford University PressNew York, NY, 2006. http://dx.doi.org/10.1093/oso/9780195300956.003.0009.

Full text

Abstract:

Abstract International comparisons of pharmaceutical prices are playing an increasing role in public policy toward the pharmaceutical industry. Many countries including Italy, Spain, Portugal, and Canada refer to prices of drugs in other countries when setting allowable prices in their own country. In the United States, the Congress and many other consumer organizations have been eager to know if U.S. drug prices are higher than those in other industrial countries. Although earlier studies (e.g., Reekie 1984, Schut and Van Bergeijk 1986, Szuba 1986, Pharmacy Freedom Fund 1990, U.S. Department

APA, Harvard, Vancouver, ISO, and other styles

"Certified (Listed) Patents and Approval of Generic Drugs." In Pharmaceutical, Biotechnology and Chemical Inventions, edited by Duncan Bucknell. Oxford University PressOxford, 2011. https://doi.org/10.1093/9780199289011.003.0078.

Full text

Abstract:

Abstract This chapter outlines the regulatory frameworks for data exclusivity, generic drug approval, and patent linkage in Australia, Canada, Japan, and the United States. Australia provides a five-year exclusivity period under the Therapeutic Goods Administration (TGA) and requires patent-related certificates for generic applicants, who must also demonstrate reasonable efforts to confirm non-infringement. It describes Canada’s Patented Medicines Regulations, which link drug approval with patent rights through judicial review rather than trial. The chapter details Japan’s informal system base

APA, Harvard, Vancouver, ISO, and other styles

Musto, David F. "State And Local Narcotic Control." In The American Disease, Origins Of Narcotic Control. Oxford University PressNew York, NY, 1999. http://dx.doi.org/10.1093/oso/9780195125092.003.0005.

Full text

Abstract:

Abstract Early local and state narcotic controls in the United States grew out of the danger perceived by those American communities that were directly affected. Pennsylvania, the home of leading morphine manufacturers, enacted an antimorphine law as early as 1860. Two decades later Ohio passed a law against smoking opium, and in 1897, twelve years after the way had been prepared by pharmaceutical research for massive production of the com pound, Illinois enacted a law against cocaine.1 Soon thereafter, as the activity of the American Pharmaceutical Association between 1901 and 1903 suggests,

APA, Harvard, Vancouver, ISO, and other styles

FitzGerald, G. A., Patricia Price, and H. R. Knapp. "BIOCHEMICAL AND FUNCTIONAL EFFECTS OF DIETARY SUBSTRATE MODIFICATION IN MAN11Supported by Grant HL 30400 from the National Institutes of Health. Dr. FitzGerald is an Established Investigator of the American Heart Association. Dr. Knapp holds a Faculty Development Award from the Pharmaceutical Manufacturers' Association Foundation." In Health Effects of Polyunsaturated Fatty Acids in Seafoods. Elsevier, 1986. http://dx.doi.org/10.1016/b978-0-12-644360-8.50008-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical Manufacturers Association of Canada"

Crosby, Tamer, John Wolodko, and Haralampos Tsaprailis. "Gap Analysis of Canadian Pipeline Coatings: A Review Study." In CORROSION 2016. NACE International, 2016. https://doi.org/10.5006/c2016-07488.

Full text

Abstract:

Abstract Coatings are one of the main methods to protect pipelines primarily from corrosion and wear. There exist several coating technology systems and the desired properties of a good coating will change from one application to another. It is estimated that the value of the protective coatings market is around $3-4 billion dollars in Canada. Therefore, analyzing the protective coating sector for potential opportunities becomes significant. In this review paper, we investigate the pipeline coatings sector in order to determine gaps in currently available coating technologies. The objective is

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Pharmaceutical Manufacturers Association of Canada"

Lubowa, Nasser, Zita Ekeocha, Stephen Robert Byrn, and Kari L. Clase. Pharmaceutical Industry in Uganda: A Review of the Common GMP Non-conformances during Regulatory Inspections. Purdue University, 2021. http://dx.doi.org/10.5703/1288284317442.

Full text

Abstract:

The prevalence of substandard medicines in Africa is high but not well documented. Low and Middle-Income Countries (LMICs) are likely to face considerable challenges with substandard medications. Africa faces inadequate drug regulatory practices, and in general, compliance with Good Manufacturing Practices (GMP) in most of the pharmaceutical industries is lacking. The majority of pharmaceutical manufacturers in developing countries are often overwhelmed by the GMP requirements and therefore are unable to operate in line with internationally acceptable standards. Non-conformances observed durin

APA, Harvard, Vancouver, ISO, and other styles

(Archived), Irina Ward, and Farah Abu Saleh. PR-473-144506-R01 State of the Art Alternatives to Steel Pipelines. Pipeline Research Council International, Inc. (PRCI), 2017. http://dx.doi.org/10.55274/r0011459.

Full text

Abstract:

This report is a literature review of several non-metallic material systems often used as alter-natives to steel pipelines. The pipeline systems reviewed are high density polyethylene (HDPE), fiberglass reinforced plastic (FRP), flexible composite and thermoplastic liners. This report is not intended to be a detailed guide or design manual on the use of the referenced materials for pipeline applications, rather an overall evaluation on the current state of these systems. Significant industry literature and documentation already exists on the design, manufacturing, installation, and operation o

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!